AK112 (PD-1/VEGF-a bispecific antibody) combined with chemotherapy in locally advanced pancreatic cancer: a case report
The combination therapy of AK112 and AG achieved good results in this case, but the broader efficacy of this regimen across the pancreatic cancer population awaits validation through large-scale clinical trials. The ongoing trials are highly anticipated, as successful results could establish AK112 as a novel therapeutic strategy for pancreatic cancer.
Authors
- Beiyuan Hu
- Jiuliang Yan
- Chuntao Wu
- Zihao Qi (ORCID: https://orcid.org/0009-0009-8107-4768)
- Jiang Long (ORCID: https://orcid.org/0009-0000-6048-0737)
- Hanguang Dong
- Haitao Gu
- Tao Chen
- Huijiang Zhou
Institutions
- Shanghai Jiao Tong University (CN)
- Shanghai Chest Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-01-09
- DOI
- https://doi.org/10.3389/fonc.2025.1667445
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00